Home › Idiopathic Thrombocytopenic Purpura › Connecticut
Idiopathic Thrombocytopenic Purpura clinical trials in Connecticut
3 studies for Idiopathic Thrombocytopenic Purpura are looking for participants at sites in Connecticut.
Cities in Connecticut
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
- Yale Cancer Center, New Haven
- Stamford Hospital, Stamford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07421167Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Yale New Haven Hospital, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07104565A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Yale University School of Medicine, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 1, 2026 · NCT06544499From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.